INTRODUCTION
============

Gastric cancer (GC) remains the fifth most common malignancy and the third leading cause of cancer death worldwide^\[[@B1],[@B2]\]^, despite its global declining rate. GC is usually diagnosed at later stages of the disease, which is associated with poor prognosis^\[[@B3]\]^. Therefore, understanding the molecular mechanisms of gastric carcinogenesis is of crucial essence in identifying biomarkers for early screening, diagnosis, and monitoring of disease progression.

The gastrointestinal (GI) lining is constantly exposed to the harsh luminal contents, including microbial, chemical and mechanical stress inducers^\[[@B4]\]^. Hence, it is designed to constantly undergo self-renewal^\[[@B5]\]^. This relentless replenishment of the GI epithelium is owed to a limited number of uniquely designed resident adult stem cells that are programmed to provide the specific architecture and function required by the GI tract^\[[@B6]\]^. Tissue homeostasis and regeneration of the GI epithelium are strongly governed, in the adult stem cells, by the balance in cell proliferation, cell cycle arrest, and cell migration^\[[@B7]\]^. These targeted adult stem cells reside in specialized microenvironments, called the stem cell niches, that regulate the frequency and timing of cell-renewal^\[[@B8]\]^. However, during tumor development, intrinsic and/or extrinsic factors interrupt the normal replenishment process, which leads to dysregulation of the homeostatic balance and uncontrollable cell growth^\[[@B9]\]^. As a result, stem cells, when driven out of balance, may serve to seed tumor development^\[[@B10],[@B11]\]^.

The Wnt signalling pathway is a critical regulator in the homeostasis of GI tissues^\[[@B12]-[@B14]\]^. The interaction between its multiple ligands regulates the final strength of the resulting signal, which results in the activation of a subset of transcription factors, controlling the stem cells' identity and/or differentiation fate^\[[@B15]\]^. The leucine-rich G-protein coupled receptor (LGR5) has been identified as a target gene of the Wnt signalling pathway, which is owed to its promoter-containing multiple binding sites for the T-cell factor/lymphoid enhancer factor (TCF)/β catenin transcription complex^\[[@B16]\]^. Cell surface expression of LGR5 (in association with R-spondin) strengthens the Wnt signalling pathway, resulting in a stemness-predominant state^\[[@B17]\]^, which may potentiate the carcinogenic process by enhancing the cellular regeneration of tumors, such as that of the intestine^\[[@B18],[@B19]\]^. Overexpression of LGR5 has been documented in various carcinomas, including hepatocellular^\[[@B20]\]^, colon and rectum^\[[@B21]\]^, as well as oesophagus^\[[@B22]\]^. Another target gene of Wnt pathway is TROY (a member of the TNF-receptor superfamily)^\[[@B16]\]^, with a dual function, one activating the NFkB signalling pathway^\[[@B23]\]^, the other forming an inhibitory complex with LGR5 in the cellular membranes, which may modulate the Wnt signalling cascade^\[[@B16]\]^. Dysregulation of TROY expression has also been reported for several other malignancies such as melanomas^\[[@B24]\]^, glioblastomas^\[[@B25]\]^, and squamous cell carcinomas^\[[@B26]\]^. Recent studies on the function of TROY in GI cancers have mostly focused on colorectal cancer^\[[@B16],[@B23],[@B27]\]^, in which the role of Wnt signalling differs from that of gastric tissue. Fafilek and colleagues^\[[@B16]\]^, having carried out chromatin co-percipitation and DNA microarray studies on various colorectal cancer cell lines, demonstrated the co-precipitation of TROY and LGR5. Additional siRNA studies led them to conclude that TROY may act as a negative modulator of the Wnt signalling pathway, in LGR5-positive stem cells^\[[@B16]\]^. The function of TROY in GC is poorly understood. Nevertheless, Wilhelm *et al.*^\[[@B28]\]^ evaluated the expression of TROY in GC patients by immunohistochemistry and qRT-PCR and demonstrated its loss of expression in tumor tissue, as well as loss of colony formation ability in a TROY-over-expressing GC cell line.

In the present study, we aimed to evaluate the proposed negative modulatory role of TROY on LGR5 expression, by studying their simultaneous expression in the neoplastic and non-tumoral adjacent tissues of GC patients, at various stages of disease. We, then, assessed this incident at late versus early time points, following *H. pylori* infection, in a mouse model. Collectively, our data manifests the up-regulation of LGR5 in gastric carcinogenesis, coincident with down-regulation of TROY.

MATERIALS AND METHODS
=====================

**Patients**

Our study population included 30 patients with histologically confirmed intestinal GC admitted at Cancer Institute, Tehran University of Medical Sciences, Iran. Data and sample collection was performed following the provision of written informed consent, according to the protocols approved by the National Committee on Ethical Issues in Medical Research, Ministry of Health and Medical Education of Iran; Ref No. 315. Patient identifiers were kept confidential. Demographic information, including age, gender, ethnicity, family history of GC, and smoking habits were obtained via personal interviews ([Table 1](#T1){ref-type="table"}). Gastric tissue from the tumor (neoplastic) and the corresponding adjacent (non-tumoral) regions were obtained following partial or total gastrectomy.

**Serologic assays**

Fasting venous blood was collected from each subject, prior to gastric surgery. The sera were isolated and stored at -70 °C until later measurement of anti-*H. pylori* IgG and serum pepsinogen I (sPGI) and II (sPGII) levels.

###### 

Demographic and clinicopathological characteristics of the study population

  **Characteristics**    **n (%)**
  ---------------------- -------------
  Age (y)                
  Mean ± SD              67.4 ± 5.72
  Median                 66.5
  Range (min, max)       25 (54, 79)
  Gender                 
  Female                 10 (33.3)
  Male                   20 (66.7)
  Ethnicity              
  Fars                   6 (20.0)
  Non-Fars               24 (80.0)
  Family history of GC   
  No                     19 (63.3)
  Yes                    11 (36.7)
  Smoking habits         
  Never                  20 (66.7)
  Ever                   10 (33.3)
  *H. pylori*            
  Sero-negative          6 (20.0)
  Sero-positive          24 (80.0)
  PGI/II ratio           
  \>3.0                  14 (46.7)
  ≤3.0                   16 (53.3)
  Subsite                
  Proximal               19 (63.3)
  Distal                 11 (36.7)
  Grade                  
  Well                   11 (36.7)
  Moderate               9 (30.0)
  Poor                   10 (33.3)
  Stage                  
  I                      5 (16.7)
  II                     5 (16.7)
  III                    17 (56.7)
  IV                     3 (9.9)

***H. pylori sero-status***

The presence of serum IgG against *H. pylori*was detected as previously described^\[[@B29]\]^. Subjects with borderline results were re-evaluated by a commercial ELISA kit (Trinity Biotech, Ireland).

**Serum pepsinogens**

sPGI and sPGII levels were measured by ELISA (Biohit, Finland) according to the manufacturer's instructions, and the PGI/II ratio was calculated. Serum PGI/II values were dichotomized based on the proposed cut-off value of 3.0^\[[@B30],[@B31]\]^.

**Clinicopathologic features**

Patients were classified according to the subsite as proximal or distal. Paraffin-embedded gastric tissues were sectioned, stained with H & E stain and evaluated by an expert pathologist. Gastric tumors were categorized according to their differentiation grade (well/moderate/poor)^\[[@B32]\]^ and stage of progression (I, II, III, IV) according to TNM classification (T: primary tumor, N: regional lymph nodes, M: distant metastasis)^\[[@B33]\]^.

**Bacteria**

Mouse-adapted *H. pylori* strain was grown at 37 °C under micro-aerobic conditions (10% CO~2~, 5% O~2~, and 85% N~2~) up to 72 h. The bacteria were then harvested from solid culture, suspended in Brucella Broth and incubated at 37 °C, while shaking at 150 rpm, up to 24 hours^\[[@B34]\]^.

**Mouse treatment**

Six-week-old female C57BL/6 mice (n = 54) were procured from Pasteur Institute of Iran (Tehran) and housed at the animal care facilities, in accordance with approved standards. The mice were treated as previously described for gerbils^\[35\]^. Briefly, the animals were randomized into treatment (n = 26) and sham (n = 28) groups. The former group was given 200 ppm MNU (N-methyl-N-nitrosourea, Sigma, USA) dissolved in their drinking water, for one week. They were then orally gavaged with *H. pylori* inoculums (10^8^ cfu dissolved in 200 μl of Brucella Broth) thrice, with one-day intervals. They were also fed high (10%)-salt diets, with weekly intervals, for 50 weeks thereafter. The sham-treated mice received 200 μl of Brucella Broth, instead of *H. pylori* inoculums and were fed a regular diet. Gastric tissues were collected from both groups, following euthanization by intraperitoneal injection of overdose of ketamine and xylazine (Alfasan, Woerden, Holland) at 8, 16, 26, and 50 weeks post treatment. Paraffin-embedded gastric tissues of mice were sectioned, stained with H&E stain and evaluated by an expert pathologist. Data obtained at early (8 + 16 w) and late (26 + 50 w) time points were pooled, for the sake of statistical analysis.

**Immunohistochemistry (IHC)**

Formalin-fixed and paraffin-embedded tissues were sectioned (5 μm thickness), mounted on poly-L-lysine coated slides, deparaffinized in xylene and rehydrated. Endogenous peroxidase was blocked by exposure to 3% H~2~O~2~ for 10 min, followed by antigen retrieval *via* pressurized heating in the Dako retrieval buffer (Dako, Denmark) for 1 hour. After cooling to room temperature, non-specific sites were blocked by exposure to 10% goat blood serum. LGR5 and TROY immune staining was performed using a rabbit polyclonal anti-LGR5 (dilution 1:400, ab75732, Abcam Inc., Cambridge, USA) and rabbit monoclonal anti-TROY antibody (dilution 1:600, ab138502, Abcam Inc., Cambridge, USA), respectively. Incubation with the primary antibody was done in a moist chamber at 4 °C. For visualization, slides were sequentially incubated with horse radish peroxidase-conjugated anti-rabbit IgG (dilution 1:1000, ab205718, Abcam Inc., Cambridge, UK) and DAB substrate kit (Dako, Denmark). The nuclei were counterstained with hematoxylin.

**Evaluation of immunostaining**

The processed immunostained sections were examined by our expert histologist, under light microscopy, in a blinded fashion. LGR5+ and TROY+ cells were scored as previously described^\[[@B36]\]^. Briefly, the two variables of (a) percentage of positively stained cells (0 \[none\], 1 \[1-25%\], 2 \[25-50%\], 3 \[\>50%:\]) and (b) the intensity of cytoplasmic staining (0 \[no staining\], 1 \[mild\], 2 \[moderate\], 3 \[strong\], with the highest intensity score being assigned when \>10% of cells stained with that intensity\] were combined to create the composite score (CS = 0-6).

**Statistical analysis**

Statistical analyses were done using SPSS 20.0 (IBM Corporation, New York, USA) and Graphpad Prism 6 (Graphpad Software, Inc., La Jolla, USA). The differences in mean CS of LGR5 and TROY expression between different groups were analyzed by Spearman's rank correlation analysis. The association between LGR5 and TROY expression and clinicopathological characteristics was evaluated by Student\'s *t*-test. Grouped histochemical data were analyzed using one-way ANOVA. A two-sided *p*value \< 0.05 was considered as statistically significant.

RESULTS
=======

**Patient composition**

Histologically confirmed intestinal type GC patients were included in this study. The demographic and clinicopathologic characteristics of the studied population are listed in [Table 1](#T1){ref-type="table"}. Briefly, the studied patients were of the median age of 66.5 years, the majority of whom were of the male gender (66.7%) and non-Fars ethnicity (80%), with no family history of GC (63.3%). Most of these patients were never-smokers (66.7%). Their gastric tumors were mostly located in the proximal region of the stomach (63%), with varying grades of differentiation and stages of progression. *H. pylori*-seropositive subjects (80%) predominated the study population, and patients were similarly distributed among both categories of PGI/II.

**Qualitative expression of LGR5 and TROY in gastric cancer patients**

LGR5 expression in the non-tumoral adjacent tissue of GC patients was mainly localized to the gastric epithelial cells in the basal portion of the glands ([Fig. 1 A](#F1){ref-type="fig"}: 1), with higher intensity in the cell membranes ([Fig. 1A](#F1){ref-type="fig"}: 2) as opposed to their cytoplasms ([Fig. 1A](#F1){ref-type="fig"}: 3). Conversely, TROY was broadly expressed throughout the gastric epithelial layer of the non-tumoral adjacent tissue, similarly distributed amongst the glands and surface epithelium ([Fig. 1A](#F1){ref-type="fig"}: 4), in the cell membranes as well as their cytoplasm ([Fig. 1A](#F1){ref-type="fig"}: 5 and 6). Taken together, a larger proportion of morphologically differentiated cells in the gastric epithelium of the non-tumoral adjacent tissue of GC patients expressed TROY rather than LGR5.

**Quantitative expression of LGR5 and TROY in gastric tumors and non-tumoral adjacent tissues**

In this study, the immune-stained sections were evaluated and scored, based on the percentage of positively stained cells, in combination with the cytoplasmic staining intensity and reported as the composite score (CS). More detailed analysis of the CS of non-tumoral (adjacent) tissues of patients *versus* their tumoral tissue revealed down-regulation of TROY expression (from 3.3 ± 0.9 to 2.5 ± 0.9, *p* = 0.004, [Fig. 2A](#F2){ref-type="fig"}), coinciding with up-regulation of LGR5 expression (from 2.7 ± 0.9 to 3.6 ± 1.1, *p* = 0.001, [Fig. 2A](#F2){ref-type="fig"}), which resulted in a highly significant mean difference of the two molecules in the tumor tissue (*p* \< 0.0001, [Fig. 2A](#F2){ref-type="fig"}). Furthermore, we have defined a novel variable, by which the tumoral expression of the molecule of interest was normalized against their paired adjacent (non-tumoral) counterparts (tumor CS/adjacent CS), and referred to as the relative CS (RCS). Accordingly, the mean RCS of LGR5 (1.6 ± 1.1) was significantly higher than that of TROY (1.1 ± 0.6, *p* = 0.008, [Fig. 2B](#F2){ref-type="fig"}).

**The association of gastric tissue expression of LGR5 and TROY with patients' demographic and clinicopathologic characteristics**

Pearson correlation analysis demonstrated increasing expression of TROY in the tumor-adjacent normal tissue, with rising age (r = 0.362, *p* = 0.049, [Table 2](#T2){ref-type="table"}), which did not hold true for that of the tumor tissue. In patients with family history of GC, significantly higher tumoral expression of LGR5 was observed (mean CS = 4.5 ± 0.5), in reference to those without (mean CS = 3.1 ± 0.9, *p* \< 0.0001, [Table 2](#T2){ref-type="table"}). However, this result was not observed for TROY expression. Besides, no statistically significant association was observed with gender or ethnicity of the patients, or their smoking habits and expression of either of these molecules ([Table 2](#T2){ref-type="table"}).

![Immunohistochemical detection of LGR5 and TROY expression in the gastric tissue of gastric cancer patients. Overview of LGR5+ (1-3) and TROY+ (4-6) cells in (A) non-tumoral adjacent tissue. Scale bars of 1 and 4, 200 µM; 2, 3, 5, and 6, 50 µM. Representative slides of (B) LGR5 and (C) TROY immunostaining in transition from non-tumoral adjacent tissue to that of tumor, progressing from stage I to IV (scale bars 50 µM)](IBJ-23-107-g001){#F1}

Tumoral expression of LGR5 was significantly higher in *H. pylori* sero-positive patients (3.9 ± 0.9), in reference to sero-negative ones (2.7 ± 1.4, *p* = 0.01, [Table 3](#T3){ref-type="table"}). Accordingly, those with serum PGI/II ratio of ≤3.0 had higher levels of tumor LGR5 expression (3.9 ± 1.1), as compared to those above 3.0 (3.3 ± 1.0), which did not reach statistical significance (*p* = 0.095, [Table 3](#T3){ref-type="table"}). The contrary occurred for TROY, which demonstrated significantly lower levels of tumor expression, in those with serum PGI/II ratio of ≤3.0 2.6 ± 1.1), but not in those above 3.0 (3.5 ± 1.2, *p* = 0.035, [Table 3](#T3){ref-type="table"}).

Based on the anatomic location of the tumors, those in the distal stomach had a higher expression of LGR5 (4.2 ± 0.8), in reference to those in the proximal region (3.3 ± 1.1, *p* = 0.029, [Table 3](#T3){ref-type="table"}). On the other hand, TROY expression was higher in the tumor-adjacent normal tissue of the distal stomach (3.5 ± 1.1) versus the proximal (2.7 ± 0.8) region, which was borderline significant (*p* = 0.052, [Table 3](#T3){ref-type="table"}).

![Expression of LGR5 and TROY mean composite scores (CS) of (A) tumor and non-tumoral adjacent tissues and (B) relative expression (CS~tumor~/CS~adjacent~) of LGR5 and TROY. The arrows in panel A depict the inverse trend](IBJ-23-107-g002){#F2}

###### 

The association of LGR5 and TROY expression with patients' demographic characteristics

  ----------------------------------------------------------------------------------------------------------
  **Demographic**\       **Total**\   **LGR5**\       **TROY**\                                  
  **characteristics**    **(n)**      **Mean ± SD**   **Mean ± SD**                              
  ---------------------- ------------ --------------- --------------- ----------- ----------- -- -----------
  Age (correlation)                                                                              

  *p* value                           0.915                           0.189       0.049          0.773

  Gender                                                                                         

  Female                 10           2.8 ± 1.1                       3.7 ± 1.3   3.2 ± 0.9      3.0 ± 1.5

  Male                   20           2.9 ± 1.0                       3.6 ± 1.0   2.9 ± 1.0      3.1 ± 1.1

  *p*value                            0.809                           0.813       0.440          0.838

  Ethnicity                                                                                      

  Fars                   6            2.3 ± 0.8                       3.7 ± 0.5   3.5 ± 0.8      3.8 ± 1.0

  Non-Fars               24           3.0 ± 1.1                       3.6 ± 1.2   2.9 ± 1.0      2.9 ± 1.2

  *p*value                            0.165                           0.934       0.167          0.088

  Family history of GC                                                                           

  No                     19           2.8 ± 1.0                       3.1 ± 0.9   3.2 ± 1.0      3.2 ± 1.2

  Yes                    11           3.0 ± 1.2                       4.5 ± 0.5   2.7 ± 0.9      2.8 ± 1.3

  *p* value                           0.603                           \<0.0001    0.254          0.409

  Smoking Habits                                                                                 

  Never                  20           2.8 ± 1.0                       3.7 ± 1.0   3.1 ± 0.7      3.1 ± 1.4

  Ever                   10           3.1 ± 1.1                       3.6 ± 1.2   2.8 ± 1.4      3.1 ± 0.9

  *p value*                           0.395                           0.906       0.440          0.919
  ----------------------------------------------------------------------------------------------------------

ACS, adjacent composite score; TCS, tumor composite score

With regard to tumor progression, one-way ANOVA analysis identified a statistically significant association between the grade and stage of disease with TROY (*p* = 0.028) and LGR5 (*p* \< 0.0001) expression, respectively ([Table 3](#T3){ref-type="table"}). A more detailed two-by-two analysis demonstrated a statistically significant down-regulation of TROY expression, as the tumors lost differentiation (well to moderate, *p* = 0.009, [Fig. 3A](#F3){ref-type="fig"}). Of higher interest was the observation of TROY down-regulation in transition from stage I to III, simultaneous with statistically significant up-regulation of LGR5 expression (*p* = 0.019), leading to a statistically significant mean difference of expression between these two molecules at stages II and III (*p* = 0.005). This finding was also evident in representative slides of LGR5 and TROY immunostaining in transition from non-tumoral adjacent tissue to that of tumor, progressing from stage I to IV. In the course of tumorigenesis, up to stage III, an overall up-regulation of LGR5 was exhibited, simultaneous with down-regulation of TROY, ([Fig. 1B and 1C](#F1){ref-type="fig"}). At stage IV of the disease, loss of cellular differentiation was observed. These features include organelle shrinkage and polarity loss, as well as affected plasma membrane integrity, which presented a fibroblastic-like morphology ([Fig. 1B and 1C](#F1){ref-type="fig"}, stage IV).

**Gastric tissue expression of LGR5 and TROY in mice**

In light of the association of LGR5 expression with *H. pylori* seropositivity, we evaluated the gastric tissue expressions of LGR5 and TROY, in a mouse model, during early and late time points following *H. pylori* infection. Microscopic examination of the H&E slides demonstrated infiltration and accumulation of mononuclear cells at the lamina propria of the gastric mucosa as early as eight weeks post treatment ([Fig. 4A](#F4){ref-type="fig"}2), which accelerated through time and yielded the formation of structurally organized lymphoid follicles at 50 weeks post treatment ([Fig. 4A](#F4){ref-type="fig"}5). In transition from early (8-16 w) to late (26-50 w) time points post treatment, the mentioned inverse trend, which was observed in GC patients, was also observed in the treated mice ([Fig. 5](#F5){ref-type="fig"}). Such that TROY expression was down-regulated in mice, in transition from early (8-16 w) to late (26-50 w) time points post treatment (*p* \<0.0001, [Fig. 5](#F5){ref-type="fig"}), simultaneous with up-regulation of LGR5 expression of (*p* = 0.011, [Fig. 5](#F5){ref-type="fig"}), leading to a statistically significant mean difference of composite scores between these two molecules at late (26-50 w) time points (*p* = 0.002, [Fig. 5](#F5){ref-type="fig"}). This phenomenon can be observed in the representative slides of LGR5 (Panel B) and TROY (Panel C) immunostaining in transition from sham-treated state ([Fig. 4B1 and 4C1](#F4){ref-type="fig"}), to early time points ([Fig. 4B2 and 4C2](#F4){ref-type="fig"}) and progressing to late time points ([Fig. 4B3 and 4C3](#F4){ref-type="fig"}). In the course of disease progression in mice, an overall up-regulation of LGR5 was exhibited, simultaneous with down-regulation of TROY, ([Fig. 4B and 4C](#F4){ref-type="fig"}). Localization of these two molecules in the mouse gastric mucosa was similar to that of humans.

###### 

The association of LGR5 and TROY expression with clinicopathological characteristics

  ------------------------------------------------------------------------------------------------------------------
  **Demographic**\      **Total**\      **LGR5**\                      **TROY**\                         
  **Characteristics**   **(n)**         **Mean ± SD**                  **Mean ± SD**                     
  --------------------- ------------ -- --------------- -- ----------- --------------- -- ----------- -- -----------
  *H. pylori*                                                                                            

  Sero-negative         6               2.5 ± 1.0          2.7 ± 1.4                      3.2 ± 0.8      3.2 ± 1.2

  Sero-positive         24              3.0 ± 1.0          3.9 ± 0.9                      3.0 ± 1.0      3.0 ± 1.3

  *p*value                              0.344              0.010                          0.650          0.828

  PGI/II ratio                                                                                           

  \>3.0                 14              2.7 ± 1.2          3.3 ± 1.0                      3.1 ± 1.2      3.5 ± 1.2

  ≤3.0                  16              3.0 ± 0.9          3.9 ± 1.1                      2.9 ± 0.8      2.6 ± 1.1

  *p*value                              0.463              0.095                          0.467          0.035

  Subsite                                                                                                

  Proximal              19              3.0 ± 1.1          3.3 ± 1.1                      2.7 ± 0.8      2.9 ± 1.1

  Distal                11              2.6 ± 1.0          4.2 ± 0.8                      3.5 ± 1.1      3.4 ± 1.4

  *p*value                              0.366              0.029                          0.052          0.323

  Grade                                                                                                  

  Well                  11              2.6 ± 1.3          3.7 ± 0.9                      2.9 ± 1.0      3.6 ± 1.1

  Moderate              9               3.1 ± 1.1          3.3 ± 1.5                      2.9 ± 1.1      2.2 ± 1.1

  Poor                  10              2.9 ± 0.7          3.8 ± 0.8                      3.2 ± 0.9      3.2 ± 1.1

  *p*value                              0.840              0.610                          0.746          0.028

  Stage                                                                                                  

  I                     5               3.2 ± 1.3          2.6 ± 1.1                      3.6 ± 0.9      3.8 ± 1.3

  II                    5               3.0 ± 0.7          4.6 ± 0.5                      3.2 ± 0.4      3.2 ± 1.5

  III                   17              2.8 ± 1.1          3.8 ± 0.7                      2.8 ± 1.1      2.9 ± 1.0

  IV                    3               2.6 ± 1.2          2.3 ± 1.2                      3.0 ± 1.0      3.0 ± 1.2

  *p*value                              0.323              \<0.0001                       0.410          0.396
  ------------------------------------------------------------------------------------------------------------------

ACS, adjacent composite score; TCS, tumor composite score

DISCUSSION
==========

There is limited information on the interaction of LGR5 and TROY in the process of gastric carcinogenesis. Our simultaneous assessment of these two molecules in GC patients, by IHC, demonstrated that the up-regulation of LGR5 coincides with the down-regulation of TROY in the tumor tissue. Previous pertinent IHC studies on these two molecules, in GC are summarized in [Table 4](#T4){ref-type="table"}. Every previous study that has performed paired assessment of LGR5 expression in GC tumor versus its non-tumoral adjacent tissue has reported the up-regulation of LGR5 in the former tissue ([Table 4](#T4){ref-type="table"})^\[[@B36]-[@B39]\]^. In reference to immune detection of TROY expression, there is only one report by Wilhelm and colleagues^\[[@B28]\]^ who have demonstrated its down-regulation in gastric tumor, as compared to their paired non-tumoral counterparts ([Table 4](#T4){ref-type="table"}). To our knowledge, we are the first to assess the simultaneous expression of LGR5 and TROY in GC. Regarding to the clinic-pathologic features, patients with family history of GC, a risk factor for predisposition to GC^\[[@B40]\]^, manifested higher tumoral expression of LGR5. It is well known that a family history of GC potentiates the risk for developing this type of cancer, reviewed by Yusefi *et al.*^\[[@B41]\]^. In this study, we have observed that these subjects have higher tumoral expression of LGR5, which may indicate a pro-carcinogenic status. However, this hypothesis can be validated only if demonstrated in a prospective study, prior to tumor development. Of particular interest is the fact that even though all our studied patients were diagnosed with confirmed GC, amongst them, those who are seropositive for *H. pylori* infection demonstrated higher tumoral expression of LGR5. In accordance with our findings, Uehara *et al*.^\[[@B42]\]^ and Choi *et al*.^\[[@B43]\]^ have denoted increased expression of LGR5 in gastric epithelial cells of *H. pylori*-positive GC patients ([Table 4](#T4){ref-type="table"}). Concordant with *H. pylori*-induced atrophic changes of gastric secretory glands, the level of serum PG declines^\[[@B44],[@B45]\]^, such that low serum PGI/II ratio is a serum risk indicator for GC^\[[@B31],[@B46]\]^. In our study, GC patients, with low serum PGI/II ratio, as opposed to those above, expressed higher levels of LGR5 and lower levels of TROY, in their tumor tissues. With regard to the differentiation grade of GC, we found decreased TROY expression, as the tumor lost differentiation, in transition from well to moderate grade, which was not detectable in poorly differentiated tumors. In agreement with our findings, in moderately differentiated tumors, Wilhelm *et al*.^\[[@B28]\]^ observed a correlation of TROY expression with loss of tumor differentiation. Meanwhile, LGR5 expression has repeatedly been demonstrated to be associated with the tumor grade of differentiation^\[[@B36],[@B38],[@B39],[@B47]-[@B49]\]^, with differing orders. On the other hand, the stage of tumor is a commonly used index to evaluate disease progression. Here, we have observed the downward trend of TROY expression in transition from stage I to III, simultaneous with up-regulation of LGR5 expression, manifesting a clear inverse trend. The former observation for TROY has been supported by a recent study^\[[@B28]\]^, which reported a declining trend of its expression as tumor stage progresses. In reference to accelerating levels of LGR5, literature is divided into two categories. One that supports our findings of a direct association^\[[@B37],[@B39],[@B48],[@B50],[@B51]\]^ with tumor stage progression, and the other that reports the reverse^\[[@B36],[@B38]\]^. Our observation of elevated levels of LGR5 up to stage III and its decline thereafter has been denoted by others as well^\[[@B37],[@B50],[@B51]\]^. Nevertheless, both groups confirm a distinctive association between tumoral expression of LGR5 and tumor stage ([Table 4](#T4){ref-type="table"}). These results candidate both LGR5 and TROY, not only as diagnostic, but also as prognostic markers, especially since their levels correlate with the survival rate of the patients ([Table 4](#T4){ref-type="table"})^\[[@B28],[@B37]-[@B39],[@B48],[@B50],[@B51]\]^.

![Expression of LGR5 and TROY at (A) different grades of tumor differentiation and (B) stages of disease progression. The arrows in panel B depict the inverse trend](IBJ-23-107-g003){#F3}

![Representative slides of mouse gastric tissue. (A) H&E staining (scale bars: 200 µM), (B) immunodetection of LGR5 (scale bars: 50 µM), and (C) TROY (scale bars: 50 µM) expression at different time points post treatment](IBJ-23-107-g004){#F4}

![Expression of LGR5 and TROY in mice during weeks post treatment. The arrows demonstrate the inverse trend](IBJ-23-107-g005){#F5}

###### 

Review of immunohistochemistry studies on LGR5 and TROY expression in gastric cancer

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Country/**\                       **Study population**                                                                   **Results**                                        **[Application]{.ul}**                                                                                                                                                                                                
  **year**                                                                                                                                                                                                                                                                                                                                                                                            
  -------------------------------- -- ---------------------------------------------------------- --------------------------- ----------------------------------------------- -- ------------------------ -------------------------------------------------------------- ------------------------------------------------------------ --------------------------------------------------- ---- -- ---- ---
  **[LGR5]{.ul}**                                                                                                                                                                                                                                                                                                                                                                                     

  Iran\                               GC (n = 30)                                                Paired adjacent             Intestinal GC                                      M/C                      GC \> adjacent                                                 Family history of GC (yes \> no)                             Hp^+^ \> Hp^-^\                                     \-      √    √
  2019^\[This\ study\]^                                                                                                                                                                                                                                                                                                              Tumor subsite (proximal \> distal)                               

                                                                                                                                                                                                                                                                                                                                                                                                      

  USA\                                IM (n = 17)\                                               NM (n = 10)                 Hp-positive only                                   M                        GC \> Dys \>IM \>NM                                            Male \> female                                               Tumor stage (II/III \> I/IV)                        \-      √    √
  2018^\[[@B60]\]^                    Dys (n = 10)\                                                                                                                                                                                                                                                                                                                                                   
                                      GC (n = 26)                                                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                      

  Iran\                               GC (n = 94)                                                Case only                   No previous treatment                              M/C                      Case only                                                      \> 63 y \> ≤63 y                                             Tumor subtype (intestinal \> diffuse)\              \-      \-   √
  2017^\[[@B49]\]^                                                                                                                                                                                                                                                                                                                   Tumor grade (moderate \> well \> poor)                           

                                                                                                                                                                                                                                                                                                                                                                                                      

  Colombia\                           IM (n = 17)\                                               NM (n = 10)                 Hp-positive only                                   \-                       GC \> Dys \> IM \> NM                                          \-                                                           \-                                                  \-      √    √
  2017^\[[@B61]\]^                    Dys (n = 10)\                                                                                                                                                                                                                                                                                                                                                   
                                      GC (n = 26)                                                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                      

  China\                              IM (n = 16)                                                Paired adjacent             IM (lesser curvature only)                         M                        IM \< adjacent                                                 \-                                                           IM grade (3 \< 2 \< 1 \< 0)                         \-      √    √
  2017^\[[@B62]\]^                                                                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                      

  Korea\                              Dys (n = 21)\                                              NM (n = 30)                 Current Hp infection\                              \-                       GC \> Dys \> NM                                                Current Hp infection \> Hp eradicated Hp^+^ NM\> Hp^-^ NM\   Antrum \> body\                                     \-      √    √
  2016^\[[@B43]\]^                    Early GC (n = 25)                                                                      Early GC                                                                                                                                   Hp^+^ GC \> Hp^-^ GC                                         Dys (moderate \> severe \> mild \> none)                         

                                                                                                                                                                                                                                                                                                                                                                                                      

  [China]{.ul}\                       PL of GC\                                                  Adjacent\                   \-                                                 C                        \-                                                             (\> 60 y) \> (45-60 y) \> (≤45 y)\                           Tumor invasion (no \> yes)\                                 √    √
  [2016]{.ul} ^\[^ ^[@B51]^ ^\]^      (n = 377)\                                                 (n = 93)                                                                                                                                                               Male \> female                                               Tumor stage (III \> IV \> I-II)                                  
                                      Metastatic LNs of GC (n = 194)                                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                      

  China\                              GC (n = 261)                                               Paired adjacent\            \-                                                 M/C                      GC \> adjacent                                                 NS                                                           Tumor size (\> 8 \> 4-8 \< \> 4)\                           √    √
  2015^\[[@B39]\]^                                                                               ( n = 261)                                                                                                                                                                                                                          Tumor grade (poor \> moderate \> well)\                          
                                                                                                                                                                                                                                                                                                                                     Tumor stage (III-IV \> I-II)                                     

                                                                                                                                                                                                                                                                                                                                                                                                      

  China\                              GC (n = 318)                                               NM (n = 80)                 \-                                                 C                        GC \> adjacent                                                 NS                                                           Tumor grade (poor \> moderate \> well)\                     √    √
  2014^\[[@B48]\]^                                                                                                                                                                                                                                                                                                                   Tumor stage (IV \> III \> II \> I)                               

                                                                                                                                                                                                                                                                                                                                                                                                      

  China\                              GC (n = 68)                                                Case only                   Preoperative (oxaliplatin-based) chemotherapy      C                        \-                                                             NS                                                           Tumor size (\>8 \> 4-8 \> \<4)\                             \-   √
  2014^\[[@B50]\]^                                                                                                                                                                                                                                                                                                                   Tumor grade (poor \> moderate/well)\                             
                                                                                                                                                                                                                                                                                                                                     Tumor stage (III \> I-II)                                        

                                                                                                                                                                                                                                                                                                                                                                                                      

  USA\                                Hp^+^ Gastritis (n = 12)\                                  Hp^-^ M\                    \-                                                 \-                       GC/IM \> NM                                                    \-                                                           NM (Hp+ \> Hp-)                                     \-      \-   √
  2014^\[[@B63]\]^                    Hp^+^IM (n = 10)\                                          (n = 10)                                                                                                                                                                                                                                                                                             
                                      Dys (n = 6)\                                                                                                                                                                                                                                                                                                                                                    
                                      GC (n = 12)                                                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                      

  China\                              GC (n = 236)                                               Paired adjacent\            \-                                                 M/C                      GC \> adjacent                                                 \>60 y \> ≤60 y\                                             Subtype (intestinal \> mixed \> diffuse)\                   √    √
  2013^\[[@B38]\]^                                                                               (n = 236)                                                                                                                                                              Male \> female                                               Tumor grade (well/moderate \> poor)\                             
                                                                                                                                                                                                                                                                                                                                     Tumor stage (I-II \> III-IV)                                     

                                                                                                                                                                                                                                                                                                                                                                                                      

  China\                              [GC (n = 160)]{.ul}                                        NM (n = 99)                 \-                                                 \-                       \-                                                             \-                                                           Tumor differentiation\                              \-      √    √
  2013^\[[@B47]\]^                                                                                                                                                                                                                                                                                                                   (well \> moderate \> poor)\                                      
                                                                                                                                                                                                                                                                                                                                     Tumor subsite (proximal \> distal)                               

                                                                                                                                                                                                                                                                                                                                                                                                      

  China\                              IM (n = 90)\                                               Paired adjacent\            \-                                                 M/C                      All cases \> adjacent IM \> adjacent Dys with IM (yes \> no)   \>60 y \> ≤60 y\                                             Tumor Subtype (intestinal \> diffuse)\              \-      √    √
  2013^\[[@B36]\]^                    Dys (n = 53)\                                              (n = 145)                                                                                                                                                              Male \> female                                               Dys (low \> high)\                                               
                                      GC (n = 180)\                                                                                                                                                                                                                                                                                  Tumor grade (differentiated \> undifferentiated)\                
                                      GC with metastases in lymph nodes and the liver (n = 15)                                                                                                                                                                                                                                       Tumor stage (I-II \> III-IV)\                                    
                                                                                                                                                                                                                                                                                                                                     Metastasis or recurrence (No \> Yes)                             

                                                                                                                                                                                                                                                                                                                                                                                                      

  USA\                                GC (n = 35)                                                Non-GC\                     \-                                                 C                        \-                                                             All (Hp^+^ \> Hp^-^)\                                        Antrum \> oxyntic                                   \-      \-   √
  2013^\[[@B42]\]^                                                                               (n = 18)                                                                                                                                                               GC (Hp^+^ \> Hp^-^)\                                                                                                          
                                                                                                                                                                                                                                                                        Non-GC (Hp^+^ \> HP^-^)                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                                      

  Germany\                            [GC (n = 127)]{.ul}                                        Paired adjacent\            Intestinal GC                                      M/C                      Tumor \> adjacent                                              ≥71 y \> \<71 y                                              Tumor stage (III \> IV \> II \> I)                          √    √
  2012^\[[@B37]\]^                                                                               (n = 127)                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                      

  **[TROY]{.ul}**                                                                                                                                                                                                                                                                                                                                                                                     

  Iran\                               GC (n = 30)                                                Paired adjacent             Intestinal GC                                      M/C                      GC \< adjacent                                                 Age (positive correlation)                                   PG (\> 3.0) \> (≤ 3.0)\                             \-      √    √
  2019^\[This\ study\]^                                                                                                                                                                                                                                                                                                              Tumor grade (well \>moderate/poor)                               

                                                                                                                                                                                                                                                                                                                                                                                                      

  Germany\                            [GC (n = 52)]{.ul}                                         Paired adjacent (n = 52)\   \-                                                 M                        GC \< Adjacent                                                 \-                                                           Tumor grade (inverse correlation)\                          √    √
  2016^\[[@B28]\]^                                                                               Normal stomach (n = 5)                                                                                                                                                                                                              Tumor type (intestinal \> diffuse)\                              
                                                                                                                                                                                                                                                                                                                                     Tumor stage (I \>II \>III \> IV)                                 
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IHC, immunohistochemistry; Dys, gastric dysplasia; GC, gastric cancer; IM, intestinal metaplasia; LNs, lymph nodes; NM, normal mucosa; NS, not significant; PL, primary lesions; y, years;  , increased; , decreased, M, membrane; C, cytoplasm; M/C, membrane/cytoplasm; Hp, *H. pylori*

In order to evaluate the above-mentioned inverse trend of LGR5 and TROY expression following *H. pylori* infection, we investigated their gastric tissue expression in a mouse model, based on a previous study on cancer in gerbils^\[[@B35]\]^. Having done so, we again observed a highly significant down-regulation of TROY, in transition from early (8-16 w) to late (26-50 w) time points, which coincided with the up-regulation of LGR5, during the same time period. This elevation occurred in a precancerous state, where *H. pylori*, in the presence of co-carcinogens, may trigger the gastric carcinogenic process. Our latter observation is in agreement with the evidence provided by an eloquent lineage tracing study^\[[@B52]\]^, which demonstrated that *H. pylori* colonization, of mouse gastric stem cell compartment, affects their turn-over kinetics, resulting in expansion of LGR5-positive stem cell population and up-regulation of stem cell-related genes. This incident may explain our observation of increased tumoral expression of LGR5 in *H. pylori*-positive GC patients. Moreover, it has been documented that certain populations of *H. pylori* have a tropism for the progenitor cell niche^\[[@B52],[@B53]\]^. These investigators^\[[@B52],[@B53]\]^, have associated this function of *H. pylori* to its virulent capacity, in particular to CagA, which is thought to be responsible for the inhibition of tumor suppression^\[[@B54]\]^, alteration of cell polarity^\[[@B55]\]^, and/or deregulation of cellular signalling pathways^\[[@B56]\]^. To our knowledge, there is no equivalent study for the interaction between *H. pylori* and TROY expression in the mouse stomach. Thus, our study provides the first clue as to its potential negative modulatory role on the expression of LGR5 in mice.

As previously mentioned, TROY is identified as one of the Wnt target genes, which due to its promoter containing multiple consensus TCF-binding sites, was precipitated with the TCF4-specific antibody^\[[@B16]\]^. On the other hand, treatment of HEK293 cells with TROY siRNA increases phosphorylation and cellular levels of the Wnt coreceptor, lipoprotein receptor-related protein (LRP) 6, vouching for its negative regulation of Wnt signalling pathway, by reducing LRP phosphor-rylation^\[[@B16]\]^. In the absence of TROY, increased levels of LRP phosphorylation potentiate the Wnt signaling cascade, leading to the accumulation of beta-catenin and expression of Wnt signalling target genes, including LGR5^\[[@B16]\]^. Additional support for the negative modulatory role of TROY on the Wnt signalling pathway has been provided by Wilhelm *et al*.^\[[@B28]\]^, who have demonstrated that the overexpression of TROY in MKN45 cells, a GC cell line, leads to decreased clonal expansion and increased differentiation. In this regard, Wu *et al.*^\[[@B57]\]^ and Qiu *et al.*^\[[@B58]\]^ have suggested that the expression of TROY is associated with cellular differentiation in osteoblastogenesis and adipogeneisis. These reports, in addition to our observations, allow us to speculate that in response to carcinogenic stimuli, such as *H. pylori* colonization, once the negative modulation of TROY on the Wnt signalling pathway is lifted, its downstream genes including LGR5 may be over-expressed. This inverse trend may depict a process of cellular dedifferentiation and stem cell expansion potentiating malignant transformation of cells. An indicator of cellular deformation and dedifferentiation can be the decline in the level of their secretory products, i.e. gastric PGIs^\[[@B44]\]^. Further TROY down-regulation and LGR5 up-regulation in our GC patients, with low serum PGI/II levels, strengthen this hypothesis. Our observations indicate that this process is maximized at stages II and III, after which the LGR5 expression returns to its previous levels. The latter stage may reflect a time point (stage IV) at which dedifferentiated cells begin to gain a disparate differentiation fate^\[[@B59]\]^, i.e. gastric to intestinal transdifferentiation. According to these speculations, TROY and LGR5 expression levels may reflect differentiated versus dedifferentiated cellular states, respectively. This hypothesis demands further studies for assessing the expression levels of these two molecules, as GC screening markers.

Collectively, we have observed an inverse trend between TROY down-regulation and LGR5 up-regulation in GC in humans, as well as in response to *H. pylori* infection in mice. These findings provide further evidence for the negative modulatory impact of TROY on the Wnt signalling target genes, including LGR5.
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